A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Bristol-Myers Squibb
Genmab
Revolution Medicines, Inc.
Artios Pharma Ltd
Genfleet Therapeutics (Shanghai) Inc.
Incyte Corporation
Bristol-Myers Squibb
Incyte Corporation
NGM Biopharmaceuticals, Inc
Esperas Pharma Inc.
Cantargia AB
Cantargia AB
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)